MedTrace Logo

Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction

NCT01977755 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 591

Last updated 2018-04-06

No results posted yet for this study

Summary

This study explores the potential cardioprotective properties of danegaptide when administered to patients with ST-Segment elevation myocardial infarction.

Conditions

  • Focus of Study is STEMI

Interventions

DRUG

danegaptide

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Thomas Engstrom, MD, DMSci · The Heart Center, Rigshopitalet University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-12-20
Completion
2016-06-08

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01977755 on ClinicalTrials.gov